FDA Approves Treatment for Active Polyarticular Juvenile Idiopathic Arthritis
May 15th 2018Officials with the FDA announced the approval subcutaneous formulation of tocilizumab (Actemra) for treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.
Read More